Outlook Therapeutics, Inc. (OTLK)
OTLK moved a median of -0.11% 30 minutes after news, and -0.33% by the close. How OTLK actually reacts to news — the realized, point-in-time move the market made, measured across 799 labeled events over the last three years with zero look-ahead.
OTLK’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.02% | 45% | 795 |
| 30-min | -0.11% | 45% | 798 |
| 60-min | -0.02% | 48% | 798 |
| to close | -0.33% | 44% | 797 |
| Middle 50% of OTLK reactions | -2.02% to +1.64% |
|---|---|
| Median reaction (30-min) | -0.11% |
| Measured reactions | 799 |
Half of all Outlook Therapeutics, Inc. news events land between -2.02% and +1.64% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How OTLK reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 21 | -3.99% | 24% | -0.21% |
| Analyst downgrades | 13 | -3.04% | 23% | -2.40% |
| Rating reiterations | 53 | -2.41% | 32% | -1.69% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how OTLK ranks against every other measured name →
That’s how OTLK usually reacts — get an email when it moves on news →Email me when OTLK moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to OTLK's baseline. Nothing else.
Recent OTLK events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg) | Press release | GlobeNewswire | -4.21% | -0.86% | |
| Form 8-K Outlook Therapeutics, For: Sep 25 | SEC filing · Form 8-K | SEC EDGAR | -4.21% | -0.86% | |
| Form 8-K Outlook Therapeutics, For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | -3.24% | +0.15% | |
| Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand | Press release | GlobeNewswire | -0.79% | -1.49% | |
| Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment | Press release | GlobeNewswire | -0.87% | +4.16% | |
| Form 8-K Outlook Therapeutics, For: Aug 23 | SEC filing · Form 8-K | SEC EDGAR | -0.20% | -0.79% | |
| Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™ | Press release | GlobeNewswire | -0.20% | -0.79% | |
| Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference | Press release | GlobeNewswire | +3.90% | -0.29% | |
| Form 10-Q Outlook Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.41% | -2.50% | |
| Form NT 10-Q Outlook Therapeutics, For: Jun 30 | SEC filing · Form NT | SEC EDGAR | +2.50% | +4.14% | |
| Form 8-K Outlook Therapeutics, For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -2.81% | -10.36% | |
| Form 8-K Outlook Therapeutics, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -2.81% | -10.36% | |
| Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™ | Press release | GlobeNewswire | -2.81% | -10.36% | |
| Form 8-K Outlook Therapeutics, For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +4.66% | +15.58% | |
| Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants | Press release | GlobeNewswire | +4.66% | +15.58% | |
| Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants | Press release | GlobeNewswire | +4.66% | +15.58% | |
| Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026 | Press release | GlobeNewswire | +0.00% | -2.75% | |
| Form 8-K Outlook Therapeutics, For: Jul 21 | SEC filing · Form 8-K | SEC EDGAR | -1.96% | +4.07% | |
| Form 8-K Outlook Therapeutics, For: Jul 24 | SEC filing · Form 8-K | SEC EDGAR | -6.34% | -25.00% | |
| Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD | Press release | GlobeNewswire | — | -14.07% | |
| Form EFFECT Outlook Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -2.13% | -4.96% | |
| Form S-3 Outlook Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +6.32% | -2.82% | |
| Form 8-K Outlook Therapeutics, For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | -3.93% | -0.71% | |
| Form DEFA14A Outlook Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -5.36% | -6.55% | |
| Form 8-K Outlook Therapeutics, For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | +0.29% | -1.74% | |
| Form 8-K Outlook Therapeutics, For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +1.67% | +30.83% | |
| Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD | Press release | GlobeNewswire | +1.67% | +30.83% | |
| Form 8-K Outlook Therapeutics, For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | -1.86% | +12.40% | |
| Form DEF 14A Outlook Therapeutics, For: Jul 16 | SEC filing · Form DEF | SEC EDGAR | -8.09% | -9.60% | |
| Form DEFA14A Outlook Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -8.09% | -9.60% | |
| Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) | Press release | GlobeNewswire | -1.86% | +12.40% | |
| Form 8-K Outlook Therapeutics, For: May 29 | SEC filing · Form 8-K | SEC EDGAR | -1.86% | +12.40% | |
| Form 8-K Outlook Therapeutics, For: May 28 | SEC filing · Form 8-K | SEC EDGAR | +1.33% | -2.67% | |
| Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | Press release | GlobeNewswire | +1.33% | -2.67% | |
| Form 8-K Outlook Therapeutics, For: May 26 | SEC filing · Form 8-K | SEC EDGAR | -3.48% | -13.92% | |
| Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg) | Press release | GlobeNewswire | -3.48% | -13.92% | |
| Form PRE 14A Outlook Therapeutics, For: Jul 16 | SEC filing · Form PRE | SEC EDGAR | -3.48% | -13.92% | |
| Form 8-K Outlook Therapeutics, For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -1.48% | -0.35% | |
| Form 10-Q Outlook Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.48% | -0.35% | |
| Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -1.48% | -0.35% | |
| Form 8-K Outlook Therapeutics, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -7.13% | -1.10% | |
| Form D Outlook Therapeutics, | SEC filing · Form D | SEC EDGAR | +0.34% | +0.59% | |
| Form 8-K Outlook Therapeutics, For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | -1.80% | +7.25% | |
| Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering | Press release | GlobeNewswire | -1.80% | +7.25% | |
| Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | Press release | GlobeNewswire | +2.67% | +0.14% | |
| Form 8-K Outlook Therapeutics, For: Apr 21 | SEC filing · Form 8-K | SEC EDGAR | +2.67% | +0.14% | |
| Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) | Press release | GlobeNewswire | -15.01% | -18.73% | |
| Form 8-K Outlook Therapeutics, For: Apr 07 | SEC filing · Form 8-K | SEC EDGAR | -2.54% | +11.45% | |
| Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA | Press release | GlobeNewswire | -0.03% | +9.57% | |
| Form 8-K Outlook Therapeutics, For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | -2.54% | +0.48% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the OTLK section they belong to.
Where else OTLK is measured.
OTLK earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Outlook Therapeutics, Inc.'s median reaction calculated?
Every labeled OTLK news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 799 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of OTLK's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does OTLK's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.